Moderna’s melanoma vaccine trial success sparks $45 billion market value surge

Moderna’s shares jumped more than 170% after the company announced that its experimental melanoma vaccine, intismeran, met its primary goals in a Phase 3 trial. The surge added roughly $45 billion to the company’s market value, lifting the stock to levels not seen since 2024.

The trial, conducted with partner Merck, showed positive results in patients with melanoma, though detailed efficacy data were not released. Analysts said the outcome suggests the vaccine could become a multibillion‑dollar treatment and may have broader applications against other tumor types.

Analysts at RBC Capital Markets and TD Cowen called the result a "major win" and a "landmark moment," noting that the news could help restore investor confidence after a period of declining sales and low share prices.